ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 569,75
-0,82%
Dow Jones
40 211,72
0,00%
DAX
18 483,53
-0,63%
Brent Oil
82,94
-1,66%
Bitcoin
63 738,28
-1,72%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
26/10/201022h00Business WireAllos Therapeutics to Report Third Quarter 2010 Financial Results on November 4, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/10/201023h21Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/10/201023h21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/10/201016h06Dow Jones NewsAllos Granted Orphan Status In Europe For Lymphoma DrugNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/10/201015h00Business WireAllos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Hodgkin Lymphoma by the Eu...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/10/201014h19Dow Jones NewsAllos' Pralatrexate Outperforms Tarceva In Lung-Cancer StudyNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/10/201013h15Business WireAllos Therapeutics Announces Presentation of Favorable Survival Data from Randomized Phase 2b Study of FOLOTYN® in Patients ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/10/201016h00GlobeNewswire Inc.Allos Therapeutics, Inc. (ALTH) to Ring The NASDAQ Stock Market Closing BellNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/09/201022h14Edgar (US Regulatory)Amended Current report filing (8-K/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/09/201023h40Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/09/201015h00Business WireAllos Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/09/201019h29Business WireAllos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO CongressNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/09/201023h50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/09/201022h19Edgar (US Regulatory)Amended Annual Report (10-K/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/07/201022h17Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (S-8)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/07/201013h53Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/07/201013h30Business WireAllos Therapeutics Reports Second Quarter 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/07/201013h00Business WireAllos Therapeutics Announces Topline Results from Phase 2b Study of FOLOTYN in Patients with Advanced Non-Small Cell Lung CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/07/201015h00Business WireAllos Therapeutics to Report Second Quarter 2010 Financial Results on July 28, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/06/201015h00Business WireAllos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Cutaneous T-Cell Lymphoma ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/06/201017h45Business WireAllos Therapeutics’ FOLOTYN Shows Activity & Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refrac...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/06/201015h00Business WireAllos Therapeutics Reports New Data Demonstrating that Responses to FOLOTYN are Correlated with Prolonged Survival in Patient...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/06/201015h00Business WireAllos Therapeutics to Present at Four Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/06/201015h00Business WireAllos Therapeutics Announces FOLOTYN® Data Presentations at the American Society of Clinical Oncology & the Congress of the ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/05/201015h00Business WireAllos Therapeutics to Present at the Citi Investment Research Global Health Care ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
18/05/201014h52Dow Jones NewsAllos Gets Orphan-Drug Designation For Bladder Cancer DrugNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
18/05/201014h00Business WireAllos Therapeutics’ Pralatrexate Granted FDA Orphan Drug Designation for the Treatment of Bladder CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/05/201021h42Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/201022h00Business WireAllos Therapeutics Reports First Quarter 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/05/201021h22Edgar (US Regulatory)Confidential Treatment Order (CT ORDER)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

NASDAQ
OSUR
OraSure Technologies
LSE
FLOT
Is $ Flt Rte Bd
NASDAQ
AGNC
AGNC Investment
USOTC
FIND
Findex Com (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés